News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Robert Bache Joins AmeriLife as Vice President of Health

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, today announced the appointment of Robert Bache to Vice President, Health. “As AmeriLife’s Health Distribution continues to grow by leaps and bounds, it’s important that we surround our partners with the expertise and leadership to help accelerate their business,” said Scotty Elliott, Chief Distribution Officer for AmeriLife’s Health Distribution. “Having Bobby join our leadership ranks is nothing short of a coup for AmeriLife, and I’m thrilled to welcome him to our team.” A Medicare expert known throughout the industry as “Medicare Bob,” Bache has enjoyed a nearly 20-year career as an entrepreneur, author, sales strategist, industry influencer and business leader. He spent more than three years at TRANZACT as a top Medicare Supplement insurance producer before founding Senior Healthcare Direct in 2012. Under Bache's leadership, Senior Healthcare Direct has grown into a leading independent insurance broker helping thousands of beneficiaries across the country navigate, compare and enroll in the right Medicare plan options for them. In his new role, Bache will oversee a portfolio of firms within AmeriLife’s Health Distribution, helping to fortify their operations and optimize their synergies with AmeriLife. Bache will also support carrier relations, training and business development efforts for AmeriLife. As a result of Bache’s transition, David Minaya, Senior Healthcare Direct’s vice president of sales, will assume day-to-day management of the agency, reporting to AmeriLife’s President of Direct-to-Consumer, Jim Palmer. “When I joined the AmeriLife family with Senior Healthcare Direct in 2020, it was due in large part to the incredible resources and partners I would gain to help grow my business. Now, I get to help other entrepreneurs and business owners – just like myself – grow theirs, and I couldn’t be more excited for the opportunity,” said Bache. “I’m especially proud for David, and I know he, Christina Ragone [SVP of Operations], and the incredible sales, marketing and support teams will continue to flourish under Jim’s leadership.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

February 06, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

Irwin Naturals acquires Braxia Scientific to expand mental health treatment and R&D

Irwin Naturals Inc.

Irwin Naturals President Adam Berk joined Proactive's Natalie Stoberman with details of the company's acquisition of Braxia Scientific. Berk said the strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development. The combination establishes a wider footprint of 22 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the US. The newly-combined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeutics, Berk added. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 06, 2023 07:03 AM Eastern Standard Time

Video
Article thumbnail News Release

Kadimastem Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, and developing a potential cure for diabetes, has received a patent from the Australian Patent Office for production technology of AstroRx ® containing healthy functioning astrocytes for the treatment of ALS and drug screening. This patent accompanies the company's patents for the product in the US, Europe, Japan, and Israel, and is significant to have been granted before the planned phase IIa clinical trial in the US scheduled for the coming year. The patent protects the manufacturing technology of the company's leading product, AstroRx®, for the use and treatment of ALS (Amyotrophic Lateral Sclerosis). In addition, the patent protects the use of the company's platform cell-based drug screening technology to discover compounds with therapeutic potential. AstroRx® contains astrocytes, the supporting cells of the central nervous system (brain and spinal cord) whose activity is impaired in many neurological diseases such as ALS. In ALS patients, the ability of astrocytes to maintain a normal survival environment that supports the motor neurons is impaired and as a result there is massive cell loss of the motor neurons, which are responsible for the movement of the voluntary muscles. The company's assumption is that the injection of healthy, functioning astrocytes into the spinal cord fluid of ALS patients in a standard lumbar puncture procedure is expected to compensate for the dysfunction of the diseased astrocytes and support the survival of the suffering motor neurons, thereby slowing the progression of the disease. Unlike small chemical drugs that usually work with a single mechanism of action, the astrocytes operate with several different mechanisms of action at the same time, each of which individually may protect the motor neurons that are affected by the disease. Kadimastem completed a clinical trial (Phase I/IIa), in which the cells were injected into the spinal cord fluid using a standard lumbar puncture procedure in 10 ALS patients. The results of the trial demonstrated a high safety profile, as well as a clinically meaningful effect maintained over the first 3 months period after treatment, as measured by the pre vs post slope change of a clinical score known as ALS Functional Rating Score (ALSFRS-R) Asaf Shiloni, CEO of Kadimastem, commented: "The patent granted in Australia, which joins the patent we received a few months ago in the U.S., continues to strengthen our patent portfolio in the field of treatment for ALS and other neuro-degenerative diseases. This is a testimony and recognition of the innovation of the science developed at Kadimastem and we are working intensively to complete the filing of an IND submission in anticipation to begin clinical trials in the U.S.". Prof. Michel Revel, Kadimastem's Chief Scientist, said: "The ALS program continues to move forward as the company's patent technology continues to strengthen. The company's vision of providing treatment to ALS patients continues to advance, and I am confident that the science developed in the company will greatly help patients in the future." In Australia there are currently about 2,000 ALS patients, with about 730 [1] ALS patients diagnosed each year. About Kadimastem Kadimastem Ltd. is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte based cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Company Contacts: Asaf Shiloni CEO INFO@kadimastem.com For more information and/or a meeting with the company's management: Lior Gottlieb, lior@gotlive-ir.co.il, 050-9200194 [1] https://medicalrepublic.com.au/unravelling-the-complexities-of-als/57092 Contact Details Kadimastem Ltd. Asaf Shiloni INFO@kadimastem.com Company Website https://www.kadimastem.com/

February 06, 2023 07:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Avicanna says 2022 was transformational despite challenging cannabis market

Avicanna Inc

Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022. Azadian said 2022 was challenging for both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian said it was transformational year for Avicanna as it remained focused and deliver on its business plan. Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across its four business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which contributed to successful exports to 18 international markets. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 03, 2023 12:02 PM Eastern Standard Time

Video
Article thumbnail News Release

Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga A recent merger between Applied UV Inc. (NASDAQ CM: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment industry. For industry watchers, particularly investors, who are constantly on the hunt for viable investment opportunities, the merger could be on their radar, especially as such a deal can shape the sector’s future. Address A Growing UV Disinfection Market Applied UV believes that the PURO merger further positions it to address a growing air disinfection market trend that aligns with the White House Clean Air Initiatives implemented during the height of the COVID-19 pandemic. The initiative was designed to protect consumers and businesses against existing and future airborne pathogens allowing economies globally to remain open. In terms of the overwhelming opportunities the deal presents, Max Munn, CEO of Applied UV, explained in a press release that it heightened the significant synergies between Applied UV and PURO. The company's acquisition of PURO adds a powerful monitoring software platform that opens new opportunities to interconnect its portfolio of UV technology solutions. Puro already has a strong presence in various sectors, such as education, government, and healthcare. These sectors have some of the strongest growth opportunities in the category, and the company believes that specializations in these sectors complement the current sectors that Sterilumen serves — food Storage, food processing, cannabis and horticulture. “These mergers expand our addressable market significantly, and PURO’s strong, strategic relationship with Acuity and national distributors provides us with additional opportunities to advance our growth agenda and increase returns for our investors,” he said. Applied UV is eyeing being a leading player in an ever-growing UV disinfection equipment industry which also has players like Xylem Inc. (NYSE: XYL), Xenon Pharmaceuticals Inc. (NASDAQ: XENE), Halma Plc. (LON: HLMA) and Calgon Carbon Corp. Currently, there is an increase in the adoption of UV in medical care, fueling the growth of the global disinfection equipment market. The market is anticipated to reach $6.17 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. Grand View Research observed that increased government initiatives and rising demand for UV disinfection equipment from healthcare organizations will continue to drive the sector’s growth. The technology and work of companies like Applied UV can never be overlooked, especially in medical care. Increasingly, countless industries, such as healthcare, are realizing the benefits of protecting patients and preventing infection with UV light disinfection at health facilities. For example, UVC radiation emitted by UV germicidal lamps is known to effectively breach the cells of microorganisms, making them non-viable and unable to replicate or infect patients and medical personnel at hospitals. Applied UV prides itself as a global leader that applies the power of narrow-range ultraviolet light for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically. Two Subsidiaries And Segments The company’s major selling point could be its two wholly-owned subsidiaries — SteriLumen Inc. and Munn Works LLC. SteriLumen offers a portfolio of technologically advanced, energy-efficient air purifier and surface disinfectant systems: Airocide® by Sterilumen, Scientific Air™ by Sterilumen and Lumicide™ by Sterilumen. SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections. Airocide®’s applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. Targeted for use in facilities with high customer turnover, such as hospitals, hotels, commercial facilities, and other public spaces. The Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The company’s second subsidiary, Munn Works, is a global company that manufactures the highest quality mirrors and case goods. From statement pieces that have the impact of original art to meticulous high-volume production for guest rooms or multi-family projects, the company works closely with designers to achieve the perfect balance of aesthetics and economics. The company has the following reportable segments that are driving growth: Disinfection segment: The design, manufacture, assembly and distribution of disinfecting systems for use in healthcare, hospitality, food, wine, and commercial municipal and residential markets. The disinfection segment addresses heating, ventilation, and air conditioning (HVAC) in public, government, municipal, retail spaces and buildings. Hospitality segment: The manufacture of fine mirrors and furniture specifically for the hospitality industry. Applied UV’s merger with LED Supply is key here. LED Supply is a strong player in the commercial lighting space, and the company hopes to bring expertise in design and specification for the multifamily space. It complements the hospitality category and will lead to synergistic revenue opportunities for Munn Works and LED Supply. SG&A Translating Into Cost Reductions? Apart from the broader addressable market and cross-selling opportunities, including increasing revenues, the merger could present synergies that might ultimately translate into cost reductions. A cursory look at Applied UV’s financial results for Q3 2022 showed that Selling, General, and Administrative (SG&A costs for the three months ended September 30, 2022, increased to $3.5 million compared to $2.7 million for the three months ended September 30, 2021. This increase of approximately $822,000 was driven primarily by the expansion of the disinfection segment with the acquisition of KES and SciAir; the expansion of the hospitality segment with the addition of the VisionMark acquisition; and corporate segment expenses due to increased consulting, legal, accounting and infrastructure costs related to the initial integration of the operations of the company’s strategic acquisitions. SG&A costs decreased by $526,000 from last quarter, and the company anticipates efficiency gains this year as it fully integrates its acquisitions and leverages synergies where practical. With a larger team that will collaborate on sales and marketing strategies, new product development, and engineering now at its disposal, Applied UV could eye new acquisitions that could lead to revenue growth for investors and value for customers. For investors looking to invest in medical technology companies or stocks, Applied UV’s growth potential could be very attractive. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

February 03, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony discs in the lower back. While its exact cause is unknown, factors such as age, obesity, poor posture, and overuse of the lumbar spine are believed to be contributing factors. The burden of chronic lumbar disc disease is significant, with the World Health Organization estimating that up to 75% of adults will experience some form of chronic back pain throughout their lifetime. It is also estimated that 10-15% of those affected will have a long-term disability due to their condition. To address the unmet need for an effective and safe way of treating this burdensome condition, BioRestorative Therapies (NASDAQ: BRTX) launched a Phase 2 double-blind, controlled, randomized study of BRTX-100 in 99 American patients. BRTX-100 is an innovative technology that uses the patient’s cells to repair damage to discs in the back. Phasing Into Bigger Future Production? The phase 2 study is evaluating the initial efficacy and safety of a single dose of BRTX-100 compared to saline injected into the affected disk in the spine. Although the primary endpoints will be unblinded after all 99 patients have been treated, a critical milestone for BRTX is scheduled in March or April 2023 related to the safety profile of the product. An independent group of experts will assess the safety data of the first four patients treated in the study. This board of experts decides if a study can continue, if there needs to be changes in the way the study is conducted or if the study should be stopped entirely. BRTX is confident that the data from the study will show that BRTX-100 is safe in treating cLLD. The outcome of the board examination will have a critical impact on its next moves — “Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.” In anticipation of positive findings from this study, BRTX is increasing its manufacturing and quality control capacity and hiring new scientists to meet the demands for the BRTX-100 Phase 2 enrollment. The additional demand is expected not only for the phase 2 study in cLLD but for studies in other conditions affecting the neck, knee and hip. Clearing the safety hurdle of the trial enables the Company to expand its BRTX-100 platform into other indications more easily and at a greater pace. Other companies in the stem cell therapy sector of the biotech industry include Sanofi (NASDAQ: SNY), Vertex Pharmaceuticals (NASDAQ: VRTX) and BioMarin Pharmaceutical (NASDAQ: BMRN). Visit biorestorative.com for more information on the company and its product candidates. This article was originally published on Benzinga. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

February 03, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

Avricore Health looks to continue positive growth in 2023 after success in 2022

Avricore Health

Avricore Health CEO Hector Bremner joined Proactive's Steve Darling with an update on the company's 2022 performance and the goals it has set for 2023. Bremner told Proactive more about Avricore's key HealthTab offering and the scaling it saw in 2022. He also shared his vision for 2023, which includes further expansion of HealthTab with current partners, international expansion, and revenue growth and profitability. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 01:05 PM Eastern Standard Time

Video
Article thumbnail News Release

Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the exclusive license of potential monoclonal antibodies from Curia Global, a leading contract research, development and manufacturing organization. Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 12:15 PM Eastern Standard Time

Video
Article thumbnail News Release

Delivra Health Brands says Dream Water to be sold across Hilton Hotels

Delivra Health Brands Inc.

Delivra Health Brands CEO Gord Davey joined Proactive's Natalie Stoberman to announce the company's Dream Water products are being distributed across 450 Hilton Hotels in the US. Davey told Proactive that Delivra's Dream Water brand offers sleep aids in a variety of formats and formulations. Dream Water currently produces convenient, travel-friendly, single-serving 2.5oz liquid sleep shots, sleep powder packets that consumers can take with or without water, and gummies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 02, 2023 11:39 AM Eastern Standard Time

Video
1 ... 161162163164165 ... 302